Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRole of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients
Cancer Biomarkers, 09/09/09
Formica V et al. – There is a significant predictive value of CA19.9, but not of CEA and biomarker reduction, for MCRC patients treated with new antineoplastic drugs. Moreover, only patients with abnormal baseline CA19.9 levels benefited significantly from bevacizumab.
Methods- Consecutive chemotherapy-naive MCRC patients treated with either standard chemotherapy-alone (FOLFIRI/FOLFOX) or chemotherapy+bevacizumab (FOLFIRI+bevacizumab) were included in the analysis
- Patients had to have serial biweekly measurement of CEA and CA19.9 available for at least three months of treatment
- Among all evaluated factors only type of treatment (chemotherapy-alone vs chemotherapy+bevacizumab) and baseline CA19.9 (> vs < normal) were independently associated with PFS, while neither baseline CEA nor biomarker reduction during therapy reached statistical significance
- When patients with different baseline CA19.9 levels were analysed separately, only patients with abnormal CA19.9 benefited significantly from the administration of bevacizumab
Related Articles
Gender Disparities in Metastatic Colorectal Cancer Survival
Clinical Cancer Research, 10/06/09
Relevance Score: 82%
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
Journal of Cancer Research & Clinical Oncology, 11/18/09
Relevance Score: 81%
New trends in epidermal growth factor receptor-directed monoclonal antibodies
Immunotherapy, 11/06/09
Relevance Score: 81%
Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors
Clinical and Experimental Metastasis, 11/05/09
Relevance Score: 81%
Optimizing the management of metastatic colorectal cancer
Critical Reviews in Oncology/Hematology, 10/23/09
Relevance Score: 81%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Activating Peroxisome Proliferator-Activated Receptor gamma Mutant Promotes Tumor Growth In vivo by Enhancing Angiogenesis
Cancer Research, 12/20/09
Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
Cancer Research, 12/20/09
hnRNP A2 Regulates Alternative mRNA Splicing of TP53INP2 to Control Invasive Cell Migration
Cancer Research, 12/20/09
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression
Genes, Chromosomes and Cancer, 12/19/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Sunlight, hormone replacement status and colorectal cancer risk in postmenopausal women
International Journal of Cancer, 12/18/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/18/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor